Rheumatology Network's Top 5: December 3, 2022


Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2022.

Holding Methotrexate After Second COVID-19 Vaccine Dose May Be Best in Psoriatic, Rheumatoid Arthritis

Holding methotrexate after the second COVID-19 vaccine dose is associated with similar immunogenicity and a lower risk of disease flare compared with withholding methotrexate after both vaccine doses.

Trials Examining Cannabis for Pain Relief Receive Disproportionate Media Coverage, Regardless of Results

New research from a team at the Karolinska Institutet suggests media coverage of studies examining cannabis use as a method for alleviating chronic pain are the recipients of a significant level of positive media coverage, regardless of results.

High Rates of Fatigue Reported in Patients with PsA, Negatively Impacting Quality of Life

Identifying the current prevalence and effect of fatigue on patients with psoriatic arthritis may lead to new strategies designed to manage this commonly-reported symptom.

Pui Lee, MD, PhD: mTOR Inhibitors may Serve as a Potential Treatment Option for Patients with sJIA

Investigators strive to learn more about whether mTORC1 inhibitors are a feasible approach for treating patients with systemic JIA.

Kazuki Yoshida, MD, MPH, ScD: Methotrexate Access in the Post-Roe v Wade Era

In the wake of the Supreme Court’s decision to overturn Roe v Wade, results of a recent study indicated that more than half of female patients treated with methotrexate, a commonly-prescribed drug used to manage rheumatic diseases, lived in states with abortion restrictions or bans.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.